Milestone Pharmaceuticals (NASDAQ:MIST) Earns “Buy” Rating from HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $25.00 target price on the stock.

Milestone Pharmaceuticals Trading Down 1.2 %

MIST opened at $2.38 on Monday. Milestone Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $2.75. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. The firm has a market capitalization of $126.92 million, a price-to-earnings ratio of -2.94 and a beta of 1.83. The company’s 50 day moving average price is $2.02 and its two-hundred day moving average price is $1.81.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp lifted its position in shares of Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after purchasing an additional 10,000 shares during the period. National Bank of Canada FI lifted its position in shares of Milestone Pharmaceuticals by 163.4% in the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after purchasing an additional 11,600 shares during the period. PVG Asset Management Corp acquired a new position in shares of Milestone Pharmaceuticals in the 3rd quarter worth approximately $46,000. Atria Investments Inc lifted its position in shares of Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after purchasing an additional 12,430 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $73,000. 86.18% of the stock is owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.